These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22289620)

  • 21. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer.
    Wang H; Vees H; Miralbell R; Wissmeyer M; Steiner C; Ratib O; Senthamizhchelvan S; Zaidi H
    Radiother Oncol; 2009 Nov; 93(2):220-5. PubMed ID: 19767115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.
    Vandecasteele K; De Neve W; De Gersem W; Delrue L; Paelinck L; Makar A; Fonteyne V; De Wagter C; Villeirs G; De Meerleer G
    Strahlenther Onkol; 2009 Dec; 185(12):799-807. PubMed ID: 20013089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.
    Beck M; Wust P; Barelkowski T; Kaul D; Thieme AH; Wecker S; Wlodarczyk W; Budach V; Ghadjar P
    Radiat Oncol; 2017 Aug; 12(1):125. PubMed ID: 28793907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing.
    Dogan N; King S; Emami B; Mohideen N; Mirkovic N; Leybovich LB; Sethi A
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1480-91. PubMed ID: 14630288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy.
    Alongi F; Fersino S; Giaj Levra N; Mazzola R; Ricchetti F; Fiorentino A; Ruggieri R; Malfatti V; Cavalleri S; Salgarello M
    Clin Nucl Med; 2015 Nov; 40(11):e496-500. PubMed ID: 26053712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
    Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
    Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218).
    Marvaso G; Gugliandolo SG; Bellerba F; Gandini S; Corrao G; Volpe S; Rojas DP; Riva G; Zerini D; Pepa M; Fodor CI; La Rocca E; Pricolo P; Alessi S; Petralia G; Mistretta FA; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2020 Jul; 37(8):74. PubMed ID: 32725443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer.
    Martinez AA; Yan D; Lockman D; Brabbins D; Kota K; Sharpe M; Jaffray DA; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1226-34. PubMed ID: 11483333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer.
    Seppälä J; Seppänen M; Arponen E; Lindholm P; Minn H
    Radiother Oncol; 2009 Nov; 93(2):234-40. PubMed ID: 19766336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.
    Hanlon AL; Watkins Bruner D; Peter R; Hanks GE
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):51-9. PubMed ID: 11163497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET and PET/CT in radiation treatment planning for prostate cancer.
    Pinkawa M; Eble MJ; Mottaghy FM
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1033-9. PubMed ID: 21806327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: Analysis of genito-urinary and rectal toxicity.
    Sundahl N; De Meerleer G; Villeirs G; Ost P; De Neve W; Lumen N; De Visschere P; Van Eijkeren M; Fonteyne V
    Radiother Oncol; 2016 Jun; 119(3):398-404. PubMed ID: 27162160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP.
    Jingu K; Ariga H; Kaneta T; Takai Y; Takeda K; Katja L; Narazaki K; Metoki T; Fujimoto K; Umezawa R; Ogawa Y; Nemoto K; Koto M; Mitsuya M; Matsufuji N; Takahashi S; Yamada S
    BMC Cancer; 2010 Apr; 10():127. PubMed ID: 20374623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.
    Lee E; Zeng J; Miyaoka RS; Saini J; Kinahan PE; Sandison GA; Wong T; Vesselle HJ; Rengan R; Bowen SR
    Med Phys; 2017 Jul; 44(7):3418-3429. PubMed ID: 28453861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.
    Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):617-23. PubMed ID: 22079736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.